What is HC Wainwright’s Forecast for VNDA FY2026 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research note issued to investors on Monday, November 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($2.45) for the year, up from their previous estimate of ($3.03). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q4 2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($1.02) EPS.

A number of other equities analysts also recently issued reports on VNDA. B. Riley Financial reaffirmed a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price objective on the stock. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. Finally, Zacks Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.50.

Vanda Pharmaceuticals Trading Down 3.4%

NASDAQ:VNDA opened at $3.75 on Wednesday. Vanda Pharmaceuticals has a 12 month low of $3.64 and a 12 month high of $9.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.54 and a quick ratio of 1.53. The business’s fifty day moving average price is $4.73 and its 200 day moving average price is $6.18.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. The company had revenue of $69.81 million during the quarter, compared to analysts’ expectations of $69.20 million.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter worth about $46,841,000. AIGH Capital Management LLC acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at about $12,510,000. State Street Corp raised its stake in Vanda Pharmaceuticals by 16.6% during the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after acquiring an additional 500,843 shares during the last quarter. Renaissance Technologies LLC raised its stake in Vanda Pharmaceuticals by 11.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock valued at $25,979,000 after acquiring an additional 378,598 shares during the last quarter. Finally, Ieq Capital LLC acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $1,731,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.